Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

Balance Sheet: Assets
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

AbbVie Inc., consolidated balance sheet: assets (quarterly data)

US$ in millions

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Cash and equivalents 7,257 13,130 18,067 12,814 13,287 8,759 6,711 9,201 11,832 8,521 6,098 9,746 12,182 8,546 9,755 8,449 7,890 6,017 41,142 39,924 10,648 5,172 4,897
Short-term investments 28 27 2 2 3 7 11 28 47 1,440 1,474 84 67 54 22 30 60 23 244 331
Accounts receivable, net 11,472 11,724 11,949 11,155 11,412 11,491 11,473 11,254 10,743 11,237 10,733 9,977 9,281 9,914 9,588 8,822 8,416 8,354 6,362 5,428 5,529 5,482 5,680
Inventories 4,450 4,218 4,245 4,099 3,981 4,055 3,833 3,579 3,172 3,396 3,483 3,128 3,094 3,386 3,272 3,310 3,474 4,059 1,844 1,813 1,929 1,895 1,702
Prepaid expenses and other 4,578 4,717 4,608 4,932 4,541 4,540 4,460 4,401 4,570 4,506 4,721 4,993 4,333 4,099 3,932 3,562 3,169 2,803 2,410 2,354 2,060 2,307 1,803
Current assets 27,785 33,816 38,871 33,002 33,224 28,852 26,488 28,463 30,364 29,100 26,509 27,928 28,957 25,999 26,569 24,173 23,009 21,256 51,758 49,519 20,166 15,100 14,413
Investments 267 272 305 304 275 288 257 241 235 244 260 277 272 266 305 293 246 225 78 93 131 1,473 1,477
Property and equipment, net 5,141 5,023 4,980 4,989 4,934 4,943 4,931 4,935 4,893 4,958 5,075 5,110 5,130 5,161 5,193 5,248 4,986 4,908 2,961 2,962 2,894 2,879 2,860
Intangible assets, net 66,646 60,243 62,225 55,610 58,603 62,862 64,848 67,439 68,725 71,823 73,986 75,951 77,456 79,340 81,293 82,876 74,643 76,463 18,203 18,649 19,036 20,459 20,846
Goodwill 35,295 33,386 33,426 32,293 32,091 32,224 32,220 32,156 31,726 32,028 32,298 32,379 32,296 32,398 32,349 33,124 42,801 42,669 15,561 15,604 15,537 15,642 15,606
Other assets 8,288 9,197 9,067 8,513 7,094 6,198 5,800 5,571 5,382 5,033 5,083 4,884 4,747 4,808 4,792 4,851 3,936 4,009 2,638 2,288 1,677 1,589 1,567
Long-term assets 115,637 108,121 110,003 101,709 102,997 106,515 108,056 110,342 110,961 114,086 116,702 118,601 119,901 121,973 123,932 126,392 126,612 128,274 39,441 39,596 39,275 42,042 42,356
Total assets 143,422 141,937 148,874 134,711 136,221 135,367 134,544 138,805 141,325 143,186 143,211 146,529 148,858 147,972 150,501 150,565 149,621 149,530 91,199 89,115 59,441 57,142 56,769

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. AbbVie Inc. current assets decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Property and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. AbbVie Inc. property and equipment, net increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Long-term assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. AbbVie Inc. long-term assets decreased from Q1 2024 to Q2 2024 but then increased from Q2 2024 to Q3 2024 exceeding Q1 2024 level.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. AbbVie Inc. total assets decreased from Q1 2024 to Q2 2024 but then slightly increased from Q2 2024 to Q3 2024.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. AbbVie Inc. cash and equivalents decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Short-term investments Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. AbbVie Inc. short-term investments increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Accounts receivable, net Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. AbbVie Inc. accounts receivable, net decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. AbbVie Inc. inventories decreased from Q1 2024 to Q2 2024 but then increased from Q2 2024 to Q3 2024 exceeding Q1 2024 level.